We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CFRX ContraFect Corporation

0.00 (0.0%)
Dec 04 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 0.226
Ask Price 0.2261
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
ContraFect Corporation CFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.2318 19:00:00
Open Price Low Price High Price Close Price Prev Close
0.2318 0.2318
Trades Volume Avg Volume 52 Week Range
0 0 - 0.20 - 13.016
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.2318 USD

ContraFect Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.46M 10.70M - 0 -65.15M -6.09 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ContraFect News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CFRX Message Board. Create One! See More Posts on CFRX Message Board See More Message Board Posts

Historical CFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.24540.2480.200.228625164,354-0.0136-5.54%
3 Months0.670.72490.200.4471274289,872-0.4382-65.4%
6 Months1.382.210.201.51474,314-1.15-83.2%
1 Year11.88813.0160.205.534,048,196-11.66-98.05%
3 Years447.20610.400.2053.441,753,755-446.97-99.95%
5 Years189.601,060.000.2068.241,303,218-189.37-99.88%

ContraFect Description

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |